Dataset Information

The effect of CELLFOOD^TM on radiotherapy or combined chemoradiotherapy: preclinical evidence.

ABSTRACT:

Background

Based on previous observations that the nutraceutical CELLFOOD™ (CF), the 'physiological modulator' that aimed to make oxygen available 'on demand', inhibits the growth of cancer cells, this study was designed to investigate the role of CF in the regulation of hypoxia-inducible factor 1 alpha (HIF1α) and its correlated proteins, phosphoglycerate kinase 1 and vascular endothelial growth factor. Our idea was that CF, acting on HIF1α, in combination with current anticancer therapies could improve their effectiveness.

Methods

To evaluate the effect of CF in association with radiotherapy and chemotherapy, different human cancer cell lines and mice with mesothelioma were analysed by tumour growth, clonogenic assay, western blot and immunohistochemical analysis.

Results

CF in combination with radiation with or without cisplatin increases the death rate of cancer cells. In vivo, 70% of mice treated with CF before the mesothelioma graft did not show any tumour growth, indicating a possible preventive effect of CF. Moreover, in mouse mesothelioma xenografts, CF improves the effect of radiotherapy also in combination with chemotherapy treatment. Immunohistochemical analysis of tumour explants showed that HIF1α expression was reduced by the combination of CF and radiotherapy treatment and even more by the combination of CF and radiotherapy and chemotherapy treatment. Mechanistically, CF increases the fraction of oxygenated cells, making the radiotherapy more effective with a greater production of reactive oxygen species (ROS) that in turn, reduce the HIF1α expression. This effect is amplified by further increase in ROS from chemotherapy.

Conclusions

Collectively, results from preclinical trials suggest that CF could be a useful intervention to improve the efficacy of radiotherapy or combined treatment strategies and could be a promising treatment modality to counteract cancer.

SUBMITTER: Nuvoli B

PROVIDER: S-EPMC6792276 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Seven percent of UK households are estimated to own both a cat and a dog, despite a popular view that the two do not live well together. This is the first study to evaluate the effects of pheromone products Feliway FriendsTM and AdaptilTM on cat-dog interactions, in homes where owners perceived the potential for improvement in the relationship between their cat and dog. A blinded parallel randomized trial design over a 6-week period was used to evaluate the effect of each of the two products, with 17 participants in each group completing the trial. Owners reported weekly on the frequency of 10 specific undesirable interactions and seven specific desirable interactions. Total undesirable and desirable interaction scores both showed significant linear contrasts over time (undesirable score decreased; desirable score increased). Undesirable interaction scores were significantly lower (with a very large effect size) during treatment compared with baseline. There were no significant differences between the two pheromone products in relation to these outcome measures. AdaptilTM and Feliway FriendsTM were both associated with a significant decrease in: dog chasing cat/cat runs away; cat hiding from dog; cat/dog staring at the other; and dog barking at cat. With AdaptilTM a significant increase was also seen in: friendly greeting and times spent relaxed in the same room. From baseline (Week 2) to the end of the study (Week 6) there was a significant improvement in owners' perception of dog relaxation in those participants who received AdaptilTM and of cat relaxation in those participants who received Feliway FriendsTM. Similarity in the core chemical structure of the appeasing pheromones might explain the main effects, whilst different species-specific additions may explain the product-appropriate species-specific increases in relaxation scores. Specific behavioral improvements seen with AdaptilTM may reflect a greater calming of dogs in this group, reducing their interest in seeking interaction with cats in the same home and the tension in the cat as a result. In conclusion, both products appear to improve the cat-dog relationship and it would be beneficial to further study their use in combination and against placebo. If selecting one product AdaptilTM may be preferable, unless there is a particular need to increase the cat's relaxation.

Project description:ObjectiveThe systematic immune status of cancer patients undergoing immunotherapy is little known. We prospectively identified the function and differentiation traits of peripheral CD8+ T cells based on our phase 1b clinical trial (NCT03222440) of radiotherapy combined with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma (ESCC) and compared it with concurrent chemoradiotherapy (CCRT).Methods19 and 18 patients were included in the cohort of radiotherapy plus camrelizumab and cohort of CCRT treatment. By using flow cytometry, we evaluated the expression levels of PD-1, Eomes, T-bet and IFN-γ (function), CD38 and HLA-DR (activation), and differentiation subsets classified according to the expression levels of CD45RA and CD62L in peripheral CD8+ T cells before and during treatment.ResultsEffective binding of anti-PD-1 antibody camrelizumab with PD-1 on CD8+ T cells was detected during treatment. Both two treatments elevated the expression levels of activation molecules CD38 and HLA-DR on CD8+ T cells. PD-1+CD8+ T cells had more activation features than PD-1-CD8+ T cells in two groups and the treatments did not alter these differences. The two treatments activated both PD-1+ and PD-1- CD8+ T cells. PD-1+CD8+ T cells had less Naïve and TEMRA but more Tcm and Tem than PD-1-CD8+ T cells in two groups and both two treatments changed the ratio of memory T cells in PD-1+ and PD-1- cells. RT plus camrelizumab treatment reduced Naïve T cells and TEMRA subsets both in PD-1+ and PD-1- CD8+ T cells while elevated Tcm subset in PD-1+CD8+ T cells and Tem subset in PD-1-CD8+ T cells. CCRT elevated Tcm subset and reduced TEMRA subset in PD-1-CD8+ T cells while did not change any subset in PD-1+CD8+ T cells. Furthermore, patients undergoing radiotherapy plus immunotherapy were found to obtain better prognosis than those receiving CCRT.ConclusionsThis study identified the dynamic changes of systematic immune status of patients undergoing treatment. The two treatments had similar activation effects on peripheral CD8+ T cells with different PD-1 properties but had different effects on their differentiation status. These results provided potential clues to the reasons underlying the difference in prognosis of the two treatments.

Dataset Information

The effect of CELLFOOD^TM on radiotherapy or combined chemoradiotherapy: preclinical evidence.

Background

Methods

Results

Conclusions

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

The effect of CELLFOODTM on radiotherapy or combined chemoradiotherapy: preclinical evidence.

Background

Methods

Results

Conclusions

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

The effect of CELLFOOD^TM on radiotherapy or combined chemoradiotherapy: preclinical evidence.